Cyclo Therapeutics, Inc. - Common Stock (NQ:CYTH)

0.7206 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cyclo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

March 26, 2025

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the...

From Rafael Holdings, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 25, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 20, 2025

Via Benzinga

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

March 13, 2025

From Rafael Holdings, Inc.

Via GlobeNewswire

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

February 20, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Which stocks are experiencing notable movement on Monday? ↗

February 10, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

February 10, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

February 07, 2025

From Cyclo Therapeutics, Inc.

Via Business Wire

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

January 14, 2025

From Cyclo Therapeutics, Inc.

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders

December 16, 2024

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders

December 14, 2024

From Halper Sadeh LLC

Via GlobeNewswire

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

December 11, 2024

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™

From Rafael Holdings, Inc.

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders

December 10, 2024

From Halper Sadeh LLC

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders

December 05, 2024

From Halper Sadeh LLC

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 04, 2024

Via Benzinga

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024

From Cyclo Therapeutics, Inc.

Via Business Wire

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

November 06, 2024

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need

From Rafael Holdings, Inc.

Via GlobeNewswire

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

October 21, 2024

Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience

From Pacira BioSciences

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

September 06, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

September 05, 2024

From Cyclo Therapeutics

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders

August 27, 2024

From Halper Sadeh LLC

Via GlobeNewswire

August 27, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗

August 27, 2024

Via Benzinga

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

August 26, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, SDIG, ARCH, CYTH on Behalf of Shareholders

August 24, 2024

From Halper Sadeh LLC

Via GlobeNewswire

Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results ↗

August 22, 2024

Via Benzinga

Gold Down Over 1%; US Initial Jobless Claims Increase ↗

August 22, 2024

Via Benzinga

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

August 22, 2024

From Halper Sadeh LLC

Via Business Wire

Dow Jumps 100 Points; BJ's Wholesale Earnings Top Estimates ↗

August 22, 2024

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.